JP2016514148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514148A5 JP2016514148A5 JP2016501850A JP2016501850A JP2016514148A5 JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5 JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016501850 A JP2016501850 A JP 2016501850A JP 2016514148 A5 JP2016514148 A5 JP 2016514148A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- nos
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778540P | 2013-03-13 | 2013-03-13 | |
| US61/778,540 | 2013-03-13 | ||
| US201361808381P | 2013-04-04 | 2013-04-04 | |
| US61/808,381 | 2013-04-04 | ||
| PCT/US2014/025441 WO2014159911A1 (en) | 2013-03-13 | 2014-03-13 | Compositions comprising anti-cd38 antibodies and carfilzomib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514148A JP2016514148A (ja) | 2016-05-19 |
| JP2016514148A5 true JP2016514148A5 (enExample) | 2017-06-15 |
| JP6279065B2 JP6279065B2 (ja) | 2018-02-14 |
Family
ID=51625288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501850A Active JP6279065B2 (ja) | 2013-03-13 | 2014-03-13 | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160022813A1 (enExample) |
| EP (2) | EP3769783A1 (enExample) |
| JP (1) | JP6279065B2 (enExample) |
| KR (2) | KR20210043006A (enExample) |
| CN (3) | CN120860201A (enExample) |
| AU (1) | AU2014244333B2 (enExample) |
| CA (1) | CA2904630A1 (enExample) |
| ES (1) | ES2808565T3 (enExample) |
| IL (2) | IL292978A (enExample) |
| MX (1) | MX373308B (enExample) |
| MY (1) | MY175418A (enExample) |
| PL (1) | PL2968555T3 (enExample) |
| PT (1) | PT2968555T (enExample) |
| RU (2) | RU2670127C2 (enExample) |
| SG (3) | SG10201913777XA (enExample) |
| WO (1) | WO2014159911A1 (enExample) |
| ZA (1) | ZA201507310B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| ES2658953T3 (es) | 2012-09-25 | 2018-03-13 | Morphosys Ag | Combinaciones y usos de los mismos |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3421494A1 (en) * | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3105333A1 (en) * | 2018-07-10 | 2020-01-16 | Sanofi | Combination therapies against cancer targeting cd38 and tgf-beta |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| TW202606756A (zh) | 2019-12-05 | 2026-02-16 | 美商賽諾菲阿凡提斯美國有限責任公司 | 用於皮下投予之抗cd38抗體的調配物 |
| IL293615A (en) * | 2019-12-06 | 2022-08-01 | Sanofi Aventis Us Llc | Use of isatuzimab for the treatment of recurrent and/or resistant multiple myeloma |
| CN118217957A (zh) * | 2024-03-18 | 2024-06-21 | 重庆迈德凯医药有限公司 | 一种卡非佐米杂质分子印迹材料及其制备方法和卡非佐米的精制方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20070042436A1 (en) * | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| RU2402568C2 (ru) * | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| JP5616569B2 (ja) | 2004-04-15 | 2014-10-29 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 酵素阻害のための化合物 |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CN101180071A (zh) | 2004-12-07 | 2008-05-14 | 普罗特奥里克斯公司 | 抑制蛋白酶体的组合物 |
| EP1848745B1 (en) | 2005-02-18 | 2014-07-09 | Medarex, L.L.C. | Monoclonal antibodies against cd30 lacking in fucosyl residues |
| PL2860192T3 (pl) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38 |
| CN101534860B (zh) * | 2006-08-07 | 2013-03-27 | 艾伯特生物治疗学公司 | 使用抗cs1-抗体治疗多发性骨髓瘤的组合物和方法 |
| US20090270419A1 (en) | 2006-09-15 | 2009-10-29 | Janine Arts | Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |
| AU2007302448C1 (en) * | 2006-09-26 | 2019-02-14 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| PE20090993A1 (es) | 2007-08-29 | 2009-07-08 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados y derivados de los mismos |
| JP2011524421A (ja) * | 2008-06-16 | 2011-09-01 | イミュノジェン・インコーポレーテッド | 新規の相乗効果 |
| BRPI0919668A2 (pt) * | 2008-10-21 | 2018-05-29 | Onyx Therapeutics, Inc. | terapia de combinação com epóxi-cetonas de peptídeo |
| KR20160091440A (ko) * | 2008-11-13 | 2016-08-02 | 길리아드 칼리스토가 엘엘씨 | 혈액 종양에 대한 요법 |
| EP2191842A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| BRPI1013990A2 (pt) * | 2009-05-06 | 2019-04-30 | Biotest Ag | método para tratar uma doença , e, combinação anticâncer |
| NZ607473A (en) * | 2010-09-27 | 2014-11-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| UA112062C2 (uk) * | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| US9272014B2 (en) * | 2011-03-29 | 2016-03-01 | Texas Tech University System | Galectin-3C combination therapy for human cancer |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| JP6279065B2 (ja) | 2013-03-13 | 2018-02-14 | サノフイ | 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物 |
| SG10201913447SA (en) | 2013-10-31 | 2020-02-27 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| IL321343A (en) | 2019-01-28 | 2025-08-01 | Sanofi Sa | Methods of treating multiple myeloma |
| JP2023550311A (ja) | 2020-11-03 | 2023-12-01 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の処置のための、イサツキシマブの使用 |
| JP2025509343A (ja) | 2022-03-07 | 2025-04-11 | サノフィ－アベンティス・ユー・エス・エルエルシー | 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用 |
-
2014
- 2014-03-13 JP JP2016501850A patent/JP6279065B2/ja active Active
- 2014-03-13 WO PCT/US2014/025441 patent/WO2014159911A1/en not_active Ceased
- 2014-03-13 RU RU2015143462A patent/RU2670127C2/ru active
- 2014-03-13 AU AU2014244333A patent/AU2014244333B2/en active Active
- 2014-03-13 PT PT147732705T patent/PT2968555T/pt unknown
- 2014-03-13 IL IL292978A patent/IL292978A/en unknown
- 2014-03-13 KR KR1020217010487A patent/KR20210043006A/ko not_active Ceased
- 2014-03-13 SG SG10201913777XA patent/SG10201913777XA/en unknown
- 2014-03-13 CA CA2904630A patent/CA2904630A1/en not_active Abandoned
- 2014-03-13 CN CN202510798995.9A patent/CN120860201A/zh active Pending
- 2014-03-13 KR KR1020157027249A patent/KR102241868B1/ko active Active
- 2014-03-13 MX MX2015012297A patent/MX373308B/es active IP Right Grant
- 2014-03-13 SG SG10201707464SA patent/SG10201707464SA/en unknown
- 2014-03-13 EP EP20180210.5A patent/EP3769783A1/en not_active Withdrawn
- 2014-03-13 PL PL14773270T patent/PL2968555T3/pl unknown
- 2014-03-13 EP EP14773270.5A patent/EP2968555B1/en active Active
- 2014-03-13 RU RU2018134595A patent/RU2723937C2/ru active
- 2014-03-13 CN CN201480024843.3A patent/CN105407921A/zh active Pending
- 2014-03-13 SG SG11201506956TA patent/SG11201506956TA/en unknown
- 2014-03-13 IL IL241407A patent/IL241407B/en unknown
- 2014-03-13 US US14/775,641 patent/US20160022813A1/en not_active Abandoned
- 2014-03-13 MY MYPI2015702949A patent/MY175418A/en unknown
- 2014-03-13 CN CN202010773679.3A patent/CN112043826A/zh active Pending
- 2014-03-13 ES ES14773270T patent/ES2808565T3/es active Active
-
2015
- 2015-10-01 ZA ZA2015/07310A patent/ZA201507310B/en unknown
-
2016
- 2016-12-22 US US15/389,279 patent/US20170106085A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,693 patent/US20190321471A1/en not_active Abandoned
-
2021
- 2021-05-19 US US17/324,478 patent/US12533411B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506388A5 (enExample) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| JP2017048208A5 (enExample) | ||
| RU2015127089A (ru) | Композиции, содержащие антитела к cd38 и леналидомид | |
| JP2021526136A5 (enExample) | ||
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| EA201891489A1 (ru) | Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант | |
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2016536314A5 (enExample) | ||
| HRP20200745T1 (hr) | Agensi koji vezuju cd123 i njihove upotrebe | |
| NZ607473A (en) | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| JP2017528462A5 (enExample) | ||
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| HRP20191115T1 (hr) | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora | |
| JP2012136541A5 (enExample) | ||
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| WO2016022589A3 (en) | Methods for treating multiple myeloma | |
| JP2010500370A5 (enExample) | ||
| JP2020502198A5 (enExample) | ||
| HRP20201632T4 (hr) | Režimi doziranja melflufena kod raka | |
| PE20231082A1 (es) | Muteinas de il-10 y proteinas de fusion de las mismas referencia cruzada a solicitudes relacionadas | |
| JP2020533383A5 (enExample) |